367 related articles for article (PubMed ID: 34731857)
41. Renal outcome after tonsillectomy plus corticosteroid pulse therapy in patients with immunoglobulin A nephropathy: results of a multicenter cohort study.
Hoshino J; Fujii T; Usui J; Fujii T; Ohashi K; Takaichi K; Suzuki S; Ubara Y; Yamagata K
Clin Exp Nephrol; 2016 Aug; 20(4):618-627. PubMed ID: 26577676
[TBL] [Abstract][Full Text] [Related]
42. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
Zhong Z; Tang Y; Tan J; Tan L; Pei G; Qin W
Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
[TBL] [Abstract][Full Text] [Related]
43. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
44. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
45. Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.
Ni Z; Zhang Z; Yu Z; Lu F; Mei C; Ding X; Yuan W; Zhang W; Jiang G; Sun M; He L; Deng Y; Pang H; Qian J
Ren Fail; 2021 Dec; 43(1):1214-1221. PubMed ID: 34396911
[TBL] [Abstract][Full Text] [Related]
46. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
47. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
Ferraro PM; Ferraccioli GF; Gambaro G; Fulignati P; Costanzi S
Nephrol Dial Transplant; 2009 Jan; 24(1):156-60. PubMed ID: 18685141
[TBL] [Abstract][Full Text] [Related]
48. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H; Rizk DV; Perkovic V; Maes B; Kashihara N; Rovin B; Trimarchi H; Sprangers B; Meier M; Kollins D; Papachristofi O; Milojevic J; Junge G; Nidamarthy PK; Charney A; Barratt J
Kidney Int; 2024 Jan; 105(1):189-199. PubMed ID: 37914086
[TBL] [Abstract][Full Text] [Related]
49. Prospective trial of combined therapy with heparin/warfarin and renin-angiotensin system inhibitors in progressive IgA nephropathy.
Ishii T; Kawamura T; Tsuboi N; Ogura M; Utsunomiya Y; Hosoya T
Contrib Nephrol; 2007; 157():114-9. PubMed ID: 17495447
[TBL] [Abstract][Full Text] [Related]
50. A Validation Study Comparing Risk Prediction Models of IgA Nephropathy.
Ouyang Y; Zhao Z; Li G; Luo H; Xu F; Shao L; Chen Z; Yu S; Jin Y; Xu J; Shi M; Hussain HMJ; Du W; Fang Z; Pan X; Wang W; Xie J; Chen N
Front Immunol; 2021; 12():753901. PubMed ID: 34721428
[TBL] [Abstract][Full Text] [Related]
51. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
Riispere Ž; Kuudeberg A; Seppet E; Sepp K; Ilmoja M; Luman M; Kõlvald K; Auerbach A; Ots-Rosenberg M
BMC Nephrol; 2017 Mar; 18(1):89. PubMed ID: 28292274
[TBL] [Abstract][Full Text] [Related]
52. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.
Frisch G; Lin J; Rosenstock J; Markowitz G; D'Agati V; Radhakrishnan J; Preddie D; Crew J; Valeri A; Appel G
Nephrol Dial Transplant; 2005 Oct; 20(10):2139-45. PubMed ID: 16030050
[TBL] [Abstract][Full Text] [Related]
53. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy.
Tatematsu M; Yasuda Y; Morita Y; Sakamoto I; Kurata K; Naruse T; Yamamoto R; Tsuboi N; Sato W; Imai E; Matsuo S; Maruyama S
Clin Exp Nephrol; 2012 Dec; 16(6):883-91. PubMed ID: 22618296
[TBL] [Abstract][Full Text] [Related]
54. Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.
Inker LA; Heerspink HJL; Tighiouart H; Chaudhari J; Miao S; Diva U; Mercer A; Appel GB; Donadio JV; Floege J; Li PKT; Maes BD; Locatelli F; Praga M; Schena FP; Levey AS; Greene T
Am J Kidney Dis; 2021 Sep; 78(3):340-349.e1. PubMed ID: 33775708
[TBL] [Abstract][Full Text] [Related]
55. Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Rizk DV; Rovin BH; Zhang H; Kashihara N; Maes B; Trimarchi H; Perkovic V; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J
Kidney Int Rep; 2023 May; 8(5):968-979. PubMed ID: 37180505
[TBL] [Abstract][Full Text] [Related]
56. Corticosteroid therapy in patients with IgA nephropathy and impaired renal function.
Tamura S; Ueki K; Ideura H; Tsukada Y; Maezawa A; Kawai H; Wakamatsu R; Yano S; Nojima Y; Naruse T
Clin Nephrol; 2001 Mar; 55(3):192-5. PubMed ID: 11316238
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of corticosteroid therapy for IgA nephropathy patients stratified by kidney function and proteinuria.
Nagasawa Y; Yamamoto R; Shinzawa M; Shoji T; Hasuike Y; Nagatoya K; Yamauchi A; Hayashi T; Kuragano T; Moriyama T; Isaka Y
Clin Exp Nephrol; 2020 Oct; 24(10):927-934. PubMed ID: 32642919
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of Abelmoschus manihot for IgA nephropathy: A multicenter randomized clinical trial.
Li P; Lin H; Ni Z; Zhan Y; He Y; Yang H; Fang J; Wang N; Li W; Cai G; Chen Y; Zhang P; Wang X; Chen Q; Li Z; Sun X; Chen X
Phytomedicine; 2020 May; 76():153231. PubMed ID: 32535481
[TBL] [Abstract][Full Text] [Related]
59. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.
Pozzi C; Andrulli S; Del Vecchio L; Melis P; Fogazzi GB; Altieri P; Ponticelli C; Locatelli F
J Am Soc Nephrol; 2004 Jan; 15(1):157-63. PubMed ID: 14694168
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of steroid pulse therapy in combination with mizoribine following tonsillectomy for immunoglobulin A nephropathy in renally impaired patients.
Kaneko T; Shimizu A; Tsuruoka S; Iino Y; Katayama Y
J Nippon Med Sch; 2013; 80(4):279-86. PubMed ID: 23995570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
